Cargando…

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Pancreatic cancer is deadly, and new treatments are urgently needed. Pancreatic cancer, in particular, effectively escapes the immune response, which is why drugs are developed that stimulate the immune system to remove the tumor. Here, we investigated potential drug targets, the che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popp, Felix C., Capino, Ingracia, Bartels, Joana, Damanakis, Alexander I., Li, Jiahui, Datta, Rabi R., Löser, Heike, Zhao, Yue, Quaas, Alexander, Lohneis, Philipp, Bruns, Christiane J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198722/ https://www.ncbi.nlm.nih.gov/pubmed/34072549 http://dx.doi.org/10.3390/cancers13112689

Ejemplares similares

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts
por: Wuerdemann, Nora, et al.
Publicado: (2020)

Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma
por: Gebauer, Florian, et al.
Publicado: (2020)

The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2019)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Predicting the HER2 status in oesophageal cancer from tissue microarrays using convolutional neural networks
por: Pisula, Juan I., et al.
Publicado: (2023)

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
por: Damanakis, Alexander I., et al.
Publicado: (2022)

Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Knipper, Karl, et al.
Publicado: (2023)

Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival
por: Lyu, Su Ir, et al.
Publicado: (2023)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report
por: Buchner, Denise, et al.
Publicado: (2018)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
por: Damanakis, Alexander I., et al.
Publicado: (2019)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

X-linked inhibitor of apoptosis protein is a prognostic marker for a favorable outcome in three identified subsets in resectable adenocarcinoma of the pancreas
por: Knipper, Karl, et al.
Publicado: (2022)

PD-1, TIM-3, and LAG-3 Expression in T Cells in a Patient with Recurrent Ossifying Fibroma: A Case Report
por: García-Muñoz, Alejandro, et al.
Publicado: (2020)

GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy
por: Plum, Patrick Sven, et al.
Publicado: (2020)

TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells
por: Folgiero, Valentina, et al.
Publicado: (2015)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
por: Gebauer, Florian, et al.
Publicado: (2021)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma
por: Raters, Verena Maria, et al.
Publicado: (2023)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome
por: Ciraolo, Elisa, et al.
Publicado: (2022)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Tim1 and Tim3 are not essential for experimental allergic asthma
por: Barlow, J L, et al.
Publicado: (2011)

Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
por: Loeser, Heike, et al.
Publicado: (2020)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
por: Nygaard, Vigdis, et al.
Publicado: (2023)

Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1, IDO, TIM‐3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma
por: Zhang, Shifa, et al.
Publicado: (2022)

Immune regulation by Tim-3
por: Banerjee, Hridesh, et al.
Publicado: (2018)

PD-1、TIM-3、LAG-3、BTLA在结外NK/T细胞淋巴瘤中的表达及其预后价值
Publicado: (2021)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer
por: Li, Jiahui, et al.
Publicado: (2020)

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma
por: Damanakis, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_754qae6a819ubbr7kv2sub3jnh